AR010712A1 - Compuestos derivado de benzoato de diaril 1,3,4-oxadiazolona, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion - Google Patents
Compuestos derivado de benzoato de diaril 1,3,4-oxadiazolona, composicion farmaceutica que lo comprende y su uso para preparar dicha composicionInfo
- Publication number
- AR010712A1 AR010712A1 ARP990100312A ARP990100312A AR010712A1 AR 010712 A1 AR010712 A1 AR 010712A1 AR P990100312 A ARP990100312 A AR P990100312A AR P990100312 A ARP990100312 A AR P990100312A AR 010712 A1 AR010712 A1 AR 010712A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- oxadiazolone
- seizures
- pharmaceutically acceptable
- composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- -1 BENZOATE 1,3,4-OXADIAZOLONE Chemical compound 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical compound C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 title 1
- 206010010904 Convulsion Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 abstract 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical class O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Derivados de oxadiazolona que tienen la formula general (I), en donde: A es un enlace directo o -CH2O-; B es un enlace directo u oxígeno; D es -(CH2)n- o-CH2CHOHCH2-; N es un numero entero desde 1 hasta 4; R es -NR1R2 o -NR1R2R3X en donde X es unanion contrario; y R1, R2, y R3 cada uno sonindependientemente hidrogeno o alquilo C1-4; o una sal farmacéuticamente aceptable no toxica o solvato del mismo y de utilidad en el tratamiento detrastornos que son en respuesta a la apertura delos canales de potasio activados con calcio de alta conductividad (BK). Composiciones farmacéuticasque comprenden una cantidad terapéuticamente efectiva de dichos derivados en asociacion con un portador o diluyente farmacéuticamenteaceptable , dichascomposiciones utiles en un método de tratamiento de trastornos sensitivos a la actividad de dicha apertura de canal de potasio tales como isquemia,ataques, convulsiones, epilepsia, asma, síndrome del intestino irritable, migrana, lesion traumática del cerebro, lesion de la médula espinal,disfuncion erectil masculina e incontinencia urinaria. Uso de dichos derivados para la preparacion de dichas composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7296698P | 1998-01-29 | 1998-01-29 | |
| US10227498P | 1998-09-29 | 1998-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR010712A1 true AR010712A1 (es) | 2000-07-12 |
Family
ID=26753969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100312A AR010712A1 (es) | 1998-01-29 | 1999-01-27 | Compuestos derivado de benzoato de diaril 1,3,4-oxadiazolona, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6034113A (es) |
| EP (1) | EP1051173A4 (es) |
| JP (1) | JP2002527352A (es) |
| KR (1) | KR20010077838A (es) |
| CN (1) | CN1150175C (es) |
| AR (1) | AR010712A1 (es) |
| AU (1) | AU735704B2 (es) |
| BG (1) | BG104706A (es) |
| BR (1) | BR9913010A (es) |
| CA (1) | CA2318830A1 (es) |
| CO (1) | CO5090837A1 (es) |
| EE (1) | EE04089B1 (es) |
| GE (1) | GEP20032914B (es) |
| HU (1) | HUP0102025A3 (es) |
| ID (1) | ID26909A (es) |
| IL (1) | IL137518A0 (es) |
| LT (1) | LT4838B (es) |
| LV (1) | LV12559B (es) |
| NO (1) | NO317102B1 (es) |
| NZ (1) | NZ505409A (es) |
| PL (1) | PL342060A1 (es) |
| RU (1) | RU2202548C2 (es) |
| SK (1) | SK10852000A3 (es) |
| TR (1) | TR200002019T2 (es) |
| TW (1) | TW550075B (es) |
| UA (1) | UA58579C2 (es) |
| WO (1) | WO1999038510A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003525199A (ja) * | 1998-01-29 | 2003-08-26 | ブリストル−マイヤーズ スクイブ カンパニー | ジアリール１，３，４−オキサジアゾロンアミノ酸誘導体 |
| WO2000044745A1 (en) * | 1999-01-29 | 2000-08-03 | Bristol-Myers Squibb Company | Carbamate derivatives of diaryl 1,3,4-oxadiazolone |
| US6297241B1 (en) | 1999-01-29 | 2001-10-02 | Bristol-Myers Squibb Company | Carbamate derivatives of diaryl 1,3,4-oxadiazolone |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| JP2005507853A (ja) | 2001-02-20 | 2005-03-24 | ブリストル−マイヤーズ スクイブ カンパニー | Ｋｃｎｑカリウムチャンネルモジュレーター並びに片頭痛および機構的に関連する疾患の治療におけるそれらの使用 |
| CN101519386A (zh) * | 2001-04-16 | 2009-09-02 | 田边三菱制药株式会社 | 高传导率钙-活化k通道开启剂 |
| US6909027B1 (en) * | 2001-08-13 | 2005-06-21 | Perry Robins | Method of forming an in-situ film dressing and the composition of the film-forming material |
| US7119246B2 (en) * | 2002-06-25 | 2006-10-10 | Perry Robins | Method of treating acne |
| IN2014KN02583A (es) | 2012-05-16 | 2015-05-08 | Techfields Pharma Co Ltd | |
| JP5855599B2 (ja) * | 2013-04-30 | 2016-02-09 | テックフィールズ バイオケム カンパニー リミテッド | 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ |
| CN104710379B (zh) * | 2015-03-09 | 2017-01-18 | 华南理工大学 | 一种bms‑191011的合成方法 |
| JP6165816B2 (ja) * | 2015-10-01 | 2017-07-19 | テックフィールズ バイオケム カンパニー リミテッド | 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ |
| AU2018225758A1 (en) * | 2017-02-24 | 2019-09-05 | Ovid Therapeutics Inc. | Methods of treating seizure disorders |
| CN110987847B (zh) * | 2019-12-11 | 2021-02-19 | 苏州今蓝纳米科技有限公司 | 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH583213A5 (es) * | 1973-05-21 | 1976-12-31 | Ciba Geigy Ag | |
| IT1251488B (it) * | 1991-09-17 | 1995-05-15 | Mini Ricerca Scient Tecnolog | Ossa(tia)diazol- e triazol-oni(tioni) ad attivita' acaricida ed insetticida |
| US5234947A (en) * | 1991-11-07 | 1993-08-10 | New York University | Potassium channel activating compounds and methods of use thereof |
| US5547966A (en) * | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
| TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| JP2003525199A (ja) * | 1998-01-29 | 2003-08-26 | ブリストル−マイヤーズ スクイブ カンパニー | ジアリール１，３，４−オキサジアゾロンアミノ酸誘導体 |
-
1999
- 1999-01-15 UA UA2000085059A patent/UA58579C2/uk unknown
- 1999-01-15 WO PCT/US1999/000910 patent/WO1999038510A1/en not_active Application Discontinuation
- 1999-01-15 CA CA002318830A patent/CA2318830A1/en not_active Abandoned
- 1999-01-15 JP JP2000529243A patent/JP2002527352A/ja active Pending
- 1999-01-15 KR KR1020007008227A patent/KR20010077838A/ko not_active Application Discontinuation
- 1999-01-15 US US09/232,033 patent/US6034113A/en not_active Expired - Fee Related
- 1999-01-15 TR TR2000/02019T patent/TR200002019T2/xx unknown
- 1999-01-15 BR BR9913010-6A patent/BR9913010A/pt not_active IP Right Cessation
- 1999-01-15 GE GEAP19995472A patent/GEP20032914B/en unknown
- 1999-01-15 IL IL13751899A patent/IL137518A0/xx unknown
- 1999-01-15 CN CNB998024112A patent/CN1150175C/zh not_active Expired - Fee Related
- 1999-01-15 SK SK1085-2000A patent/SK10852000A3/sk unknown
- 1999-01-15 ID IDW20001421A patent/ID26909A/id unknown
- 1999-01-15 EP EP99902290A patent/EP1051173A4/en not_active Withdrawn
- 1999-01-15 PL PL99342060A patent/PL342060A1/xx unknown
- 1999-01-15 AU AU22308/99A patent/AU735704B2/en not_active Ceased
- 1999-01-15 EE EEP200000447A patent/EE04089B1/xx not_active IP Right Cessation
- 1999-01-15 RU RU2000122733/04A patent/RU2202548C2/ru not_active IP Right Cessation
- 1999-01-15 NZ NZ505409A patent/NZ505409A/en unknown
- 1999-01-15 HU HU0102025A patent/HUP0102025A3/hu unknown
- 1999-01-27 TW TW088101231A patent/TW550075B/zh not_active IP Right Cessation
- 1999-01-27 AR ARP990100312A patent/AR010712A1/es not_active Application Discontinuation
- 1999-01-28 CO CO99004746A patent/CO5090837A1/es unknown
-
2000
- 2000-07-14 LT LT2000068A patent/LT4838B/lt not_active IP Right Cessation
- 2000-07-26 NO NO20003825A patent/NO317102B1/no not_active IP Right Cessation
- 2000-08-03 LV LVP-00-103A patent/LV12559B/en unknown
- 2000-08-22 BG BG104706A patent/BG104706A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EE04089B1 (et) | 2003-08-15 |
| HUP0102025A2 (hu) | 2001-11-28 |
| CN1289249A (zh) | 2001-03-28 |
| NZ505409A (en) | 2003-08-29 |
| JP2002527352A (ja) | 2002-08-27 |
| LT2000068A (en) | 2001-03-26 |
| CA2318830A1 (en) | 1999-08-05 |
| US6034113A (en) | 2000-03-07 |
| HUP0102025A3 (en) | 2002-01-28 |
| WO1999038510A1 (en) | 1999-08-05 |
| NO20003825L (no) | 2000-07-26 |
| CN1150175C (zh) | 2004-05-19 |
| AU2230899A (en) | 1999-08-16 |
| BR9913010A (pt) | 2001-05-08 |
| BG104706A (en) | 2001-04-30 |
| UA58579C2 (uk) | 2003-08-15 |
| SK10852000A3 (sk) | 2002-02-05 |
| KR20010077838A (ko) | 2001-08-20 |
| IL137518A0 (en) | 2001-07-24 |
| NO20003825D0 (no) | 2000-07-26 |
| LT4838B (lt) | 2001-08-27 |
| NO317102B1 (no) | 2004-08-09 |
| EE200000447A (et) | 2001-12-17 |
| RU2202548C2 (ru) | 2003-04-20 |
| EP1051173A4 (en) | 2002-07-31 |
| EP1051173A1 (en) | 2000-11-15 |
| PL342060A1 (en) | 2001-05-21 |
| LV12559A (en) | 2000-11-20 |
| AU735704B2 (en) | 2001-07-12 |
| TW550075B (en) | 2003-09-01 |
| LV12559B (en) | 2001-04-20 |
| CO5090837A1 (es) | 2001-10-30 |
| TR200002019T2 (tr) | 2000-11-21 |
| ID26909A (id) | 2001-02-15 |
| GEP20032914B (en) | 2003-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR010712A1 (es) | Compuestos derivado de benzoato de diaril 1,3,4-oxadiazolona, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| AP1739A (en) | Azaindoles | |
| AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
| HK1011685A1 (en) | Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents | |
| IL176107A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| EA200100623A1 (ru) | Кетолидные антибиотики | |
| TW200602040A (en) | Method of treating schizophrenia and/or glucoregulatory abnormalities | |
| DE69933897D1 (de) | Carbamat und Carbazat Ketolid Antibiotika | |
| WO2003072066A3 (en) | Compositions and methods for the treatment of glaucoma and ocular hypertension | |
| HK1046365A1 (zh) | 用於治療乾眼的脂毒素a4及類似物 | |
| NZ512526A (en) | 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin. | |
| SE0102055D0 (sv) | New Compounds | |
| SI1534352T1 (sl) | Vsadek za transport in sproščanje farmakoloških učinkovin, kot tudi postopek za proizvodnjo le-tega | |
| GB9309719D0 (en) | Therapeutic agents | |
| GB2407504A (en) | Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections | |
| EA200500398A1 (ru) | ПРОЛЕКАРСТВО ИНГИБИТОРА β-ЛАКТАМАЗЫ | |
| PT1337246E (pt) | Utilizacao de compostos de 6-dimetilaminometil-1-fenilciclohexano para terapia da incontinencia urinaria | |
| GB0019008D0 (en) | Therapeutic compounds | |
| WO2005035500A3 (en) | Therapeutic agents useful for treating pain | |
| EA200001028A1 (ru) | Производные 2"-деоксигигромицина | |
| YU24603A (sh) | Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin | |
| AR044482A1 (es) | Profarmacos inhibidores de beta-lactamasa | |
| WO2005020935A3 (en) | Method and composition of administering radioprotectants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |